Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

androgen receptor inhibitor ONCT-534

An orally bioavailable dual-action androgen receptor (AR) inhibitor, with potential antineoplastic activity. Upon oral administration, AR inhibitor ONCT-534 targets and binds to both the ligand-binding domain (LBD) and the N-terminal domain (NTD) of the AR, and inhibits AR-mediated signaling and induces the degradation of AR and AR splice variant (AR-SV) proteins. This may inhibit cell growth in AR-overexpressing tumor cells, including those with AR amplification, mutations in the AR LBD, and AR-SVs with loss of the AR LBD. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells.
Synonym:AR inhibitor ONCT-534
DAARI ONCT-534
dual-action androgen receptor inhibitor ONCT-534
Code name:ONCT 534
ONCT-534
ONCT534
Search NCI's Drug Dictionary